Jiajin Biopharmaceutical (Shanghai) Co., Ltd.
PrivateLast Round
Series B++
Jun 5, 2026
Total Funding Raised
$6.29M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Jiajin Biopharmaceutical (Shanghai) Co., Ltd. is a biotechnology company that specializes in antibody-small nucleic acid coupled drugs and brain-delivery platforms for the treatment of genetic and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Jiajin Biopharmaceutical (Shanghai) Co., Ltd. Comparables
Compare Jiajin Biopharmaceutical (Shanghai) Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aerska | 83% | |
| Gate2Brain | 80% | |
| Vect-Horus | 78% |
Jiajin Biopharmaceutical (Shanghai) Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B++ | Jun 5, 2026 | ||||
| Series B Extension | Dec 26, 2025 | ||||
| Series B | Aug 19, 2025 | ||||
| Series A++ | Apr 3, 2025 | ||||
| Series A Extension | Nov 8, 2024 | ||||
Series A | Jun 15, 2024 |
Jiajin Biopharmaceutical (Shanghai) Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shanghai Science and Technology Innovation Group | Series B++ |
| Legend Capital | Series B Extension, Series B++ |
| Frees Fund | Series B++, Angel |
| Sunshine Insurance Group | Series B++, Series B |
| MPC | Series B++, Angel |
| Lilly Asia Ventures | Series B++ |
| Qingsong Capital | Series B++ |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 26, 2025
Raised Series B Extension with Legend Capital and YuanBio Venture Capital.
- Apr 3, 2025
YuanBio Venture Capital participated in the round.
Jiajin Biopharmaceutical (Shanghai) Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Jiajin Biopharmaceutical (Shanghai) Co., Ltd.'s valuation, stock price, and market status.
Is Jiajin Biopharmaceutical (Shanghai) Co., Ltd. a public or private company?
Jiajin Biopharmaceutical (Shanghai) Co., Ltd. is a private company.
What is the current stock price of Jiajin Biopharmaceutical (Shanghai) Co., Ltd.?
Jiajin Biopharmaceutical (Shanghai) Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.
How much is Jiajin Biopharmaceutical (Shanghai) Co., Ltd. worth (valuation)?
Valuation information for Jiajin Biopharmaceutical (Shanghai) Co., Ltd. is not publicly available.
Can I buy Jiajin Biopharmaceutical (Shanghai) Co., Ltd. stock?
Jiajin Biopharmaceutical (Shanghai) Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Jiajin Biopharmaceutical (Shanghai) Co., Ltd.'s last funding round?
Jiajin Biopharmaceutical (Shanghai) Co., Ltd.'s most recent funding round was Series B++ on June 5, 2026.
Who are the main investors in Jiajin Biopharmaceutical (Shanghai) Co., Ltd.?
Key investors in Jiajin Biopharmaceutical (Shanghai) Co., Ltd. include Frees Fund, Sunshine Insurance Group, MPC, Lilly Asia Ventures.
Will Jiajin Biopharmaceutical (Shanghai) Co., Ltd. IPO soon?
No public IPO plans have been announced for Jiajin Biopharmaceutical (Shanghai) Co., Ltd..
How can I track Jiajin Biopharmaceutical (Shanghai) Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Jiajin Biopharmaceutical (Shanghai) Co., Ltd.'s secondary market activity and sign up for updates.